Guggenheim analyst Vamil Divan reiterates Vera Therapeutics (NASDAQ:VERA) with a Buy and maintains $56 price target.
Guggenheim Reiterates Buy on Vera Therapeutics, Maintains $56 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.